Tokyo, Japan

Shoko Takishima

This inventor holds 1 USPTO granted patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 1985.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shoko Takishima: Innovator in Pharmaceutical Chemistry

Introduction

Shoko Takishima is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that can aid in the management of blood glucose levels. Her innovative work has led to the creation of valuable medicinal products.

Latest Patents

Shoko Takishima holds a patent for "3-Substituted-ureido-N-pyridyl benzamides." This patent includes benzamide derivatives characterized by specific structural formulas. The compounds are designed to reduce blood glucose levels, making them useful as medicines. The patent outlines a process for preparing these derivatives and pharmaceutical compositions containing them.

Career Highlights

Throughout her career, Shoko has been associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. Her work has been instrumental in advancing the company's research and development efforts in the field of diabetes treatment. With her expertise, she has contributed to the creation of innovative solutions that address critical health issues.

Collaborations

Shoko has collaborated with notable colleagues, including Yoshio Takagaki and Masuo Koizumi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research.

Conclusion

Shoko Takishima's contributions to pharmaceutical chemistry exemplify the impact of innovation in healthcare. Her dedication to developing effective medicinal compounds continues to benefit patients and the medical community.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…